The pivotal Phase 2 studies of Romidepsin [8] and Belinostat [9] demonstrated a small number of patients with peripheral T-cell lymphoma had remarkably durable responses, but there are as yet no established biomarkers to predict response to HDAC inhibitors and potentially guide therapy [5]. This evidence concerns the gene HDAC9 and peripheral T-cell lymphoma, not otherwise specified.